Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82441 | 1.00 | ADRB1 (0.61) | ADRB1ALDH1A1MAPTRECQLMEN1 | |
| SCHEMBL28567064 | 1.00 | ADRB1 (0.61) | ADRB1ALDH1A1MAPTRECQLMEN1 | |
| Lithium SCHEMBL31448685 | 0.98 | ADRB1 (0.59) | ADRB1ALDH1A1MAPTRECQLMEN1 | |
| SCHEMBL21065781 | 0.98 | ADRB1 (0.59) | ADRB1ALDH1A1MAPTRECQLMEN1 | |
| Bromide SCHEMBL4039488 | 0.98 | ADRB1 (0.59) | ADRB1ALDH1A1MAPTRECQLMEN1 | |
| SCHEMBL327765 | 0.97 | ADRB1 (0.64) | ADRB1ALDH1A1MAPTRECQLMEN1 | |
| Hydrochloric Acid SCHEMBL16446845 | 0.95 | ADRB1 (0.61) | ADRB1ALDH1A1MAPTRECQLMEN1 | |
| SCHEMBL18118476 | 0.92 | ADRB1 (0.64) | ADRB1ALDH1A1MAPTRECQLMEN1 | |
| SCHEMBL14866966 | 0.88 | MAPT (0.50) | ADRB1ALDH1A1MAPTRECQLMEN1 | |
| SCHEMBL18806576 | 0.88 | MAPT (0.50) | ADRB1ALDH1A1MAPTRECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0543919-B1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES | SEARLE & CO (US) | 1996-04-10 | — | — | EP | claimed |
| EP-0434341-B1 | Diazine derivatives | ZENECA LTD (GB) | 1995-05-17 | — | — | EP | claimed |
| US-5252567-A | Cardiovascular disorders, sino-atrial node effects | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-12 | — | — | US | claimed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | claimed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | claimed |
| EP-0434341-A1 | Diazine derivatives | ZENECA LIMITED (GB) | 1991-06-26 | — | — | EP | claimed |
| CN-122011026-A | Asymmetric bidentate phosphine ligand and synthesis method thereof | 淮北师范大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-119751410-A | Method for thoroughly reducing aromatic oxide | 郑州大学 | 2025-04-04 | — | — | CN | disclosed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4008790-B1 | MONOAZO DYES WITH CYCLIC AMINE AS FLUORESCENCE QUENCHERS | ENZO BIOCHEM INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | disclosed |
| EP-0499266-A1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-19 | — | — | EP | disclosed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | disclosed |
| EP-0470256-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1992-02-12 | — | — | EP | disclosed |
| WO-1991013089-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-05 | — | — | WO | disclosed |
| EP-0434341-A1 | Diazine derivatives | ZENECA LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
| EP-0029286-A1 | Pyrrolo(3,4-c)quinoline derivatives, processes therefor, and pharmaceutical compositions | ICI AMERICAS INC. (US) | 1981-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | ADRB1 4475/4885ALDH1A1 2924/4885MAPT 3676/4885 |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | ADRB1 4080/4885ALDH1A1 3144/4885MAPT 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.